High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib - Trial NCT06394674
Access comprehensive clinical trial information for NCT06394674 through Pure Global AI's free database. This Phase 2 trial is sponsored by Changhai Hospital and is currently Recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 84 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Changhai Hospital
Timeline & Enrollment
Phase 2
May 01, 2024
Sep 01, 2026
Primary Outcome
Objective Response Rate(ORR)
Summary
This is a prospective, randomised, uncontrolled phase II clinical trial planned to include 84
 subjects with metastatic lung adenocarcinoma that had progressed after first- or second-line
 treatment with Osmertinib, who were randomly assigned to trial group 1 and trial group 2, and
 were given Furmonertinib 160 mg and 240 mg once/day, orally, respectively, with efficacy
 evaluated every 6 weeks until disease progression, intolerable toxic side effects, or
 Subjects voluntarily withdrew informed consent.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06394674
Non-Device Trial